Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant. Cohort 1 will consist of patients who have undergone liver transplant for MASH cirrhosis who developed recurrent MASH. Cohort 2 will consist of subjects who have undergone liver transplant for indications other than MASH cirrhosis who developed de novo MASH.

NCT Number	NCT07335601
Lead Sponsor	Madrigal Pharmaceuticals, Inc.
Conditions	MASH - Metabolic Dysfunction-Associated Steatohepatitis
Enrollment	120 participants
Start Date	2025-12-29
Primary Completion	2028-08 (estimated)
Study Completion	2029-03 (estimated)
Updated on ClinicalTrials.gov	2026-07-31